YILMAZ, F. Et Al. 2024. Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer. BMC CANCER , vol.24, no.1 .

YILMAZ, F., YAŞAR, S., Tatar, O. D., Yildirim, H. C., Guven, D. C., AKYILDIZ, A., ... Chalabiyev, E.(2024). Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer. BMC CANCER , vol.24, no.1.

YILMAZ, FERİDE Et Al. "Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer," BMC CANCER , vol.24, no.1, 2024

YILMAZ, FERİDE Et Al. "Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer." BMC CANCER , vol.24, no.1, 2024

YILMAZ, F. Et Al. (2024) . "Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer." BMC CANCER , vol.24, no.1.

@article{article, author={FERİDE YILMAZ Et Al. }, title={Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer}, journal={BMC CANCER}, year=2024}